The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications

Indian Journal of Urology

Volumn 28, Issue 1, 2012, Pages 9-14

  Ramos, Juan A ^a   Bianco, Fernando J ^b  

^a UNIVERSIDAD DE CARABOBO   (Venezuela)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Androgen antagonists; cannabinoids; cannabis; investigational therapies; prostatic neoplasms

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANDROGEN RECEPTOR; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTATE SPECIFIC ANTIGEN; RIMONABANT;

ANALGESIA; APOPTOSIS; BONE PAIN; CANCER CELL; CANCER INHIBITION; CANCER PAIN; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFUSION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; GLEASON SCORE; HUMAN; IMMUNOREACTIVITY; LIGAND BINDING; MEDLINE; NAUSEA; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVIEW; SEDATION; SIDE EFFECT; UNSTEADINESS; XEROSTOMIA;

EID: 84860478732     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.94942     Document Type: Review

References (70)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Devane WA, Dysarz FA 3 rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13. (Pubitemid 19007296)
4. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: What we know and what we need to know. Ann Intern Med 1993;119:914-23. (Pubitemid 23316877)
5. Espey DK, Wu XC, Swan J, Wiggins C, Jim MA, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007;110:2119-52. (Pubitemid 350100734)
6. Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007;167:2497-502. (Pubitemid 350254910)
7. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27. (Pubitemid 38812419)
8. Dawson N. Overview of treatment for advanced prostate cancer. Uptodate, 2010; v. 2010.
9. Sartor AO DS. Assessment and management of bone metastases in advanced prostate cancer. Uptodate, 2010; v. 2010.
10. Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, et al. Society of Urologic Oncology position statement: Redefining the management of hormone-refractory prostate carcinoma. Cancer 2005;103:11-21. (Pubitemid 39665452)
11. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5.
12. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
13. Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 2006;4:239-57.
14. Mechoulam R, Gaoni Y. Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 1965;21:1223-9.
15. Abel E. Marijuana: The first twelve thousand years. New York: Plenum Press; 1980.
16. Di Marzo V, Petrocellis LD. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006;57:553-74. (Pubitemid 43262007)
17. Zias J, Stark H, Sellgman J, Levy R, Werker E, Breuer A, et al. Early medical use of cannabis. Nature 1993;363:215.
18. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
19. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5. (Pubitemid 23305569)
20. ProCon.org. 14 Legal Medical Marijuana States and DC Laws, Fees, and Possession Limits. ProCon.org, 2010; v. 2010.
21. Dixit VP, Sharma VN, Lohiya NK. The effect of chronically administered cannabis extract on the testicular function of mice. Eur J Pharmacol 1974;26:111-4.
22. Kolodny RC, Masters WH, Kolodner RM, Toro G. Depression of plasma testosterone levels after chronic intensive marihuana use. N Engl J Med 1974;290:872-4.
23. Chakravarty I. Enzymatic changes in the male reproductive organs by delta-9-tetrahydrocannabinol. Biochem Pharmacol 1982;31:415-8. (Pubitemid 12222383)
24. Chakravarty I, Ghosh JJ. Influence of cannabis and delta-9- tetrahydrocannabinol on the biochemistry of the male reproductive organs. Biochem Pharmacol 1981;30:273-6. (Pubitemid 11142602)
25. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001;15:2745-7.
26. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003;111:43-50. (Pubitemid 36134847)
27. Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000;6:313-9. (Pubitemid 30148624)
28. Guzman M. Cannabinoids: Potential anticancer agents. Nat Rev Cancer 2003;3:745-55. (Pubitemid 37328813)
29. Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001;61:5784-9. (Pubitemid 32769095)
30. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005;65:1635-41. (Pubitemid 40478586)
31. Lamb DJ, Weigel NL, Marcelli M. Androgen receptors and their biology. Vitam Horm 2001;62:199-230. (Pubitemid 33805705)
32. Wang LG, Liu XM, Kreis W, Budman DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997;57:714-9. (Pubitemid 27085656)
33. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16. (Pubitemid 17147932)
34. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 2006;281:39480-91. (Pubitemid 46041908)
35. Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L, et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 2009;45:174-82.
36. Herkenham M. Localization of cannabinoid receptors in brain and periphery. In: Pertwee R, editor. Cannabinoid receptors. London: Academic Press; 1995.
37. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-31. (Pubitemid 38063771)
38. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61.
39. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 2009;8:403-21.
40. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-305. (Pubitemid 40629049)
41. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-80. (Pubitemid 27337346)
42. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002;66:101-21. (Pubitemid 34743589)
43. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007;10:870-9. (Pubitemid 47013432)
44. Farquhar-Smith WP, Egertová M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 2000;15:510-21. (Pubitemid 30436925)
45. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999;92:1171-5. (Pubitemid 29292557)
46. Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study. Neuroscience 1999;90:923-31. (Pubitemid 29156757)
47. Lever IJ, Rice AS. Cannabinoids and pain. Handb Exp Pharmacol 2007;177:265-306.
48. Hohmann AG, Martin WJ, Tsou K, Walker JM. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci 1995;56:2111-8.
49. Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects. J Neurosci 1996;16:6601-11. (Pubitemid 26337381)
50. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 2005;168:509-54.
51. Walker JM, Huang SM, Strangman NM, Tsou K, Sañudo-Peña MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999;96:12198-203. (Pubitemid 29502881)
52. Martin BR. Structural requirements for cannabinoid-induced antinociceptive activity in mice. Life Sci 1985;36:1523-30. (Pubitemid 15108036)
53. Fride E, Feigin C, Ponde DE, Breuer A, Hanus L, Arshavsky N, et al. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol 2004;506:179-88. (Pubitemid 39592916)
54. Farquhar-Smith WP. Do cannabinoids have a role in cancer pain management? Curr Opin Support Palliat Care 2009;3:7-13.
55. Hald A, Ding M, Egerod K, Hansen RR, Konradsen D, Jørgensen SG, et al. Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Pharmacol Biochem Behav 2008;91:38-46.
56. Hamamoto DT, Giridharagopalan S, Simone DA. Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol 2007;558:73-87. (Pubitemid 46328873)
57. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 2003;103:175-86. (Pubitemid 36579097)
58. Potenzieri C, Harding-Rose C, Simone DA. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 2008;1215:69-75.
59. Porter AC, Felder CC. The endocannabinoid nervous system: Unique opportunities for therapeutic intervention. Pharmacol Ther 2001;90:45-60. (Pubitemid 32622840)
60. Noyes R Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;18:84-9.
61. Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975;15:139-43.
62. Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M. Adjunctive nabilone in cancer pain and symptom management: A prospective observational study using propensity scoring. J Support Oncol 2008;6:119-24. (Pubitemid 351459979)
63. McNeill JA, Sherwood GD, Starck PL. The hidden error of mismanaged pain: A systems approach. J Pain Symptom Manage 2004;28:47-58. (Pubitemid 38829672)
64. Potter VT, Wiseman CE, Dunn SM, Boyle FM. Patient barriers to optimal cancer pain control. Psychooncology 2003;12:153-60. (Pubitemid 36362043)
65. Portenoy RK MZ, Ahmed E. Cancer pain management: General principles and risk management for patients receiving opioids. Uptodate, 2010; v. 2010.
66. World Health Organization. Cancer Pain Relief, 2nd ed. Geneva: World Health Organization; 1996.
67. Manchikanti L. National drug control policy and prescription drug abuse: Facts and fallacies. Pain Physician 2007;10:399-424. (Pubitemid 46971294)
68. Hornby AP, Sharma M, Stegman B. Standardized natural product cannabis in pain management and observations at a Canadian compassion society: A case report. Cases J 2009;2:7487.
69. Califano J. Califano calls for fundamental shift in attitudes and policies about substance abuse and addiction. In: (CASA) TNCoAaSAaCU, ed.: The National Center on Addiction and Substance Abuse at Columbia University (CASA); 2007.
70. Califano J. High Society: How Substance Abuse Ravages American and What to Do About It. New York: Perseus Publishing; 2007.